Christian Marsolais

Company: Theratechnologies Inc.

Job title: Senior Vice President & Chief Medical Officer

Seminars:

“SORTI”ing Out the Benefits of Leveraging SORT1 Targeting PDC to Unlock New Therapeutic Options in Oncology 8:30 am

Discussing the SORT 1 receptor in cancer as a novel target and how exploitation of one of its main biological functions as a sorting/trafficking/scavenger protein facilitates rapid internalization of its ligands, within minutes, to deliver cytotoxic payloads inside cancer cells Considering the unique MOA and safety profile of TH1902, its potential for combination with other…Read more

day: Day Two